

Supporting Information for

Anti-PD-L1 DNA Aptamer Antagonizes the Interaction of PD-1/PD-L1 with Antitumor Effect

Tian Gao^{1,2}, Zheng Mao^{2,3}, Wenjing Li^{1,2}, Renjun Pei^{1,2*}

¹ School of Nano-Tech and Nano-Bionics, University of Science and Technology of China, Hefei, 230026, China. E-mail: rjpei2011@sinano.ac.cn.

² CAS Key Laboratory of Nano-Bio Interface, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China.

³ Department of Polymer Materials, School of Materials Science and Engineering, Shanghai University, Shanghai, 200444, China




Figure S1. Sequences alignment analysis result by Clustalx 1.8.3 (a) and MEME Suite (b).




Figure S2 Affinity analysis of aptamer PL1 and antibody atezolizumab interacted with PD-L1 by SPR. SPR sensorgram (a) demonstrated interaction of different concentrations of aptamer PL1 (10 nM, 20 nM, 80 nM and 160 nM) with PD-L1 protein. SPR sensorgram (b) demonstrated interaction of different concentrations of antibody atezolizumab with PD-L1 protein: (1) 25 nM, (2) 50 nM, (3) 100 nM, (4) 200 nM and (5) 400 nM.




Figure S3 The docking stimulation for the complex structure of aptamer PL1 and PD-L1 protein (PDB: 4Z18) (a) and the analysis of interaction sites (b).




Figure S4. The serum stability of free aptamer PL1 (PL1) and phosphorothioate modified aptamer PL1 (*PL1) in 10% FBS at 37 °C for 0, 6, 24, 36 and 48 h was evaluated by ultrafiltration centrifuge (a) and native PAGE using 12% polyacrylamide gel (b). The 1-5 and 6-10 bands represent the free PL1 and phosphorothioate modified aptamer PL1 (*PL1) respectively at 48, 36, 24, 6 and 0 h.




Figure S5. Binding assays of selected aptamer PL1 with CT26 cells.




Fig. S6 The HE staining of the tissues from the healthy mice and PL1-treated mice. The scale bar in the images is 200 μm.